Design, synthesis and biological evaluation of indoline-maleimide conjugates as potential antitumor agents for the treatment of colorectal cancer

IF 3.3 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Jielin Tang , Yuxin Zhang , Lingling Zhou , Xiangrui Song , Yusi Wei , Ji Qi , Jianmin Wu , Zengqiang Song , Lingling Zhan
{"title":"Design, synthesis and biological evaluation of indoline-maleimide conjugates as potential antitumor agents for the treatment of colorectal cancer","authors":"Jielin Tang ,&nbsp;Yuxin Zhang ,&nbsp;Lingling Zhou ,&nbsp;Xiangrui Song ,&nbsp;Yusi Wei ,&nbsp;Ji Qi ,&nbsp;Jianmin Wu ,&nbsp;Zengqiang Song ,&nbsp;Lingling Zhan","doi":"10.1016/j.bmc.2024.117786","DOIUrl":null,"url":null,"abstract":"<div><p>An efficient protocol for direct coupling of maleimides and indolines at the C7-position was achieved under Rh(III) catalysis. Thirty four novel indoline-maleimide conjugates were prepared in good to excellent yields using this method. All compounds were evaluated for their anti-proliferative effect against colorectal cell lines. Among them, compound <strong>3ab</strong> showed the most potent anti-proliferative activity against the CRC cells, and displayed low toxicity in the normal cell. Further investigation indicated that <strong>3ab</strong> could effectively suppress the proliferation and migration of CRC cells, along with inducing cell cycle arrest and apoptosis. Mechanistic studies revealed that compound <strong>3ab</strong> inhibited the proliferation of CRC cells via suppressing the AKT/GSK-3β pathway. <em>In vivo</em> evaluation demonstrated remarkable antitumor effect of <strong>3ab</strong> (10 mg/kg) in the HCT116 xenograft model with no obvious toxicity, which is superior to that of 5-Fluorouracil (20 mg/kg). Therefore, conjugate <strong>3ab</strong> could be considered as a potential CRC therapy agent for further development.</p></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0968089624002001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

An efficient protocol for direct coupling of maleimides and indolines at the C7-position was achieved under Rh(III) catalysis. Thirty four novel indoline-maleimide conjugates were prepared in good to excellent yields using this method. All compounds were evaluated for their anti-proliferative effect against colorectal cell lines. Among them, compound 3ab showed the most potent anti-proliferative activity against the CRC cells, and displayed low toxicity in the normal cell. Further investigation indicated that 3ab could effectively suppress the proliferation and migration of CRC cells, along with inducing cell cycle arrest and apoptosis. Mechanistic studies revealed that compound 3ab inhibited the proliferation of CRC cells via suppressing the AKT/GSK-3β pathway. In vivo evaluation demonstrated remarkable antitumor effect of 3ab (10 mg/kg) in the HCT116 xenograft model with no obvious toxicity, which is superior to that of 5-Fluorouracil (20 mg/kg). Therefore, conjugate 3ab could be considered as a potential CRC therapy agent for further development.

Abstract Image

吲哚啉-马来酰亚胺共轭物作为治疗结直肠癌的潜在抗肿瘤药物的设计、合成和生物学评价
在 Rh(III) 催化下,实现了马来酰亚胺与吲哚啉在 C7 位直接偶联的高效方案。利用该方法制备了 34 种新型吲哚啉-马来酰亚胺共轭物,收率从良好到极佳。评估了所有化合物对结直肠癌细胞株的抗增殖作用。其中,化合物 3ab 对 CRC 细胞的抗增殖活性最强,而对正常细胞的毒性较低。进一步的研究表明,3ab 能有效抑制 CRC 细胞的增殖和迁移,并诱导细胞周期停滞和凋亡。机理研究表明,化合物 3ab 通过抑制 AKT/GSK-3β 通路抑制了 CRC 细胞的增殖。体内评价显示,3ab(10 mg/kg)在HCT116异种移植模型中的抗肿瘤效果显著,且无明显毒性,优于5-氟尿嘧啶(20 mg/kg)。因此,3ab共轭物可作为一种潜在的 CRC 治疗药物进行进一步开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Bioorganic & Medicinal Chemistry
Bioorganic & Medicinal Chemistry 医学-生化与分子生物学
CiteScore
6.80
自引率
2.90%
发文量
413
审稿时长
17 days
期刊介绍: Bioorganic & Medicinal Chemistry provides an international forum for the publication of full original research papers and critical reviews on molecular interactions in key biological targets such as receptors, channels, enzymes, nucleotides, lipids and saccharides. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of these with chemical agents. A special feature will be that colour illustrations will be reproduced at no charge to the author, provided that the Editor agrees that colour is essential to the information content of the illustration in question.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信